Small cell lung cancerNews & Research
20 curated articles for Small cell lung cancer — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Critical reviews in oncology/hematology Apr 22, 2026
Mapping the immune microenvironment of non-small cell lung cancer.
Immunotherapy is widely used in non-small cell lung cancer (NSCLC) treatment due to its significant efficacy. However, heterogeneity in treatment efficacy persists as a major challenge. The tumor immune microenvironment (TIME) crucially regulates NSCLC progression and prognosis. This article aims to...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cancer biology & medicine Apr 22, 2026
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage III non-small cell lung cancer.
The integration of immune checkpoint inhibitors has transformed the therapeutic landscape for patients with resectable and potentially resectable stage III non-small cell lung cancer, providing unprecedented opportunities for curative treatment. Several trials have investigated immune checkpoint inh...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Journal of patient-centered research and reviews Apr 21, 2026
Cryoablation as a Treatment Option for Early-Stage Primary Non-Small Cell Lung Cancer and Lung Metastases: A Narrative Review of Recent Literature.
Cryoablation has emerged as a promising treatment option for early-stage non-small cell lung cancer (NSCLC) and lung metastases. This narrative review examines recent literature on cryoablation's efficacy, safety, and outcomes in treating lung tumors. The review analyzes data from multiple clinical ...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cancer cell Apr 14, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
Small cell lung cancer (SCLC) typically displays a "cold" tumor microenvironment with a paucity of immune infiltrate. Neuroendocrine SCLC cells also profoundly repress MHC-I expression, rendering them vulnerable to NK cell-mediated cytotoxicity. Here, we confirm that neuroendocrine SCLC cells are se...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Frontiers in oncology Apr 13, 2026
Editorial: Treatment response and resistance to targeted therapies for NSCLC.
Editorial: Treatment response and resistance to targeted therapies for NSCLC.
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cancer letters Mar 15, 2026
Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies.
Small cell lung cancer (SCLC) is characterized by rapid progression, early metastasis, and poor prognosis, with a five-year survival rate of less than 7%. In recent years, advances in immunotherapy, particularly the application of immune checkpoint inhibitors (ICIs) have transformed the treatment la...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Science advances Mar 13, 2026
Subtype-specific dependencies and therapeutic opportunities in small cell lung cancer.
Small cell lung cancer (SCLC), accounting for ~15% of lung cancers, is an aggressive and lethal tumor type. It is characterized by rapid proliferation, early metastasis, and poor prognosis. Current therapies, including platinum-based chemotherapy and recently introduced immune checkpoint inhibitors,...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cell host & microbe Mar 12, 2026
Strain-level genetic heterogeneity and colonization dynamics drive microbiome therapeutic efficacy.
Fecal microbiota transplantation (FMT) has shown immunotherapeutic promise, yet its efficacy in non-small-cell lung cancer (NSCLC) remains unclear. We demonstrate that FMT improves anti-PD-1 efficacy and progression-free survival in a single-arm trial of advanced PD-L1-negative NSCLC. Analyzing over...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Trends in cancer Mar 11, 2026
Small-cell lung cancer: anatomy of an immune-cold tumor.
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine (NE) tumor and a leading cause of cancer-related morbidity. The introduction of immune checkpoint inhibitors (ICIs) transformed the treatment of many other cancers but has so far failed to benefit all but a minority of SCLC patients who g...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cancer research Mar 6, 2026
Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.
Small cell lung cancer (SCLC) is an aggressive thoracic disease characterized by rapid proliferation and early metastatic spread. The survival outcomes for patients with SCLC remain notoriously poor, underlining that only modest improvements have been achieved in clinical settings to date. However, ...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- FDA Feb 26, 2026
FDA Grants Second Approval under the National Priority Voucher Pilot Program
The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.
Why it matters: FDA announcement relevant to rare disease patients and caregivers.
- Thorax Feb 26, 2026
Rising burden of second primary lung cancers: from survivorship to secondary prevention.
Rising burden of second primary lung cancers: from survivorship to secondary prevention.
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Frontiers in oncology Feb 23, 2026
The role of antibody-drug conjugates in the treatment of lung cancer.
Over the las0t decades, lung cancer treatment has improved immensely, mainly due to the incorporation of new targeted treatments and immunotherapy. A relatively new and potentially highly effective class of drugs, antibody-drug conjugates (ADCs), has been introduced to the clinical setting and is cu...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Nature cell biology Feb 13, 2026
SLC2A1 + tumour-associated macrophages spatially control CD8 + T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
Tumour-associated macrophages (TAMs) contribute to immune checkpoint blockade resistance, but their impact on intratumoural CD8⁺ T cell distribution remains unclear. Here we show that the expression of the glucose transporter SLC2A1 is spatially negatively correlated with CD8⁺ T cell d...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Biochimica et biophysica acta. Reviews on cancer Jan 22, 2026
Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins.
Non-small cell lung cancer (NSCLC) is associated with a high incidence and mortality rate, imposing a significant economic burden worldwide. The development of standardized diagnostic and targeted therapeutic approaches is essential. Protein post-translational modifications (PTMs) play a critical ro...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- International immunopharmacology Jan 6, 2026
Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A.
Small cell lung cancer (SCLC) responds poorly to immunotherapy. This study investigates how glycolytic reprogramming drives immune evasion in SCLC by epigenetically suppressing MHC-I mediated antigen presentation. Bioinformatic and murine model studies confirmed SCLC with high ASCL1 expression (SCLC...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Biomaterials Jan 1, 2026
Nanoreactor-enabled PANoptosis via ZBP1 activation potentiates immunotherapy in non-small cell lung cancer.
Tumor immune microenvironment reconstruction and regulated cell death promotion synergistically enhance treatment outcomes in immunosuppressive non-small-cell lung cancer (NSCLC). PANoptosis, a newly identified form of immunogenic cell death that integrates the essential molecular components of pyro...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Cancer letters Dec 8, 2025
Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.
Small cell lung cancer (SCLC) is a lethal lung malignancy, which is associated with distant metastasis and chemoresistance. Due to the limited availability of targeted therapies, identifying a potential therapeutic target is a pressing unmet need in SCLC. Single-cell and bulk-transcriptomic datasets...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Thoracic surgery clinics Nov 19, 2025
Neoadjuvant, Adjuvant, or Both? Optimizing Perioperative Systemic Therapy in Lung Cancer.
The evolving landscape of perioperative systemic therapy is transforming the management of resectable non-small cell lung cancer, addressing the limitations of adjuvant chemotherapy alone, the integration of novel therapies in the adjuvant and neoadjuvant settings, and biomarker-guided approaches. I...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
- Thoracic surgery clinics Nov 19, 2025
Adjuvant Immunotherapy in Lung Cancer: Foundational Successes and Future Directions.
This comprehensive article explores the adjuvant use of immunotherapy in resectable lung cancer, specifically highlighting the impact of foundational trials including IMpower010 and KEYNOTE-091. These studies were the first to demonstrate improved survival with perioperative immunotherapy, particula...
Why it matters: Recent peer-reviewed research on Small cell lung cancer that may be relevant for patients and caregivers.
More on Small cell lung cancer
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.